Crossmark

Risk comparison of adverse reactions between gemcitabine monotherapy and gemcitabine combined with albumin-bound paclitaxel in pancreatic cancer: insights from the FDA Adverse Event Reporting System (FAERS) database

Crossref DOI link: https://doi.org/10.1186/s40360-025-00884-5

Published Online: 2025-03-19

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Jiang, Puen

Zong, Kezhen

Peng, Dadi

Zhou, Baoyong

Wu, Zhongjun
License Information

Text and Data Mining valid from 2025-03-19

Version of Record valid from 2025-03-19
More Information

Article History

Received: 21 November 2024

Accepted: 27 February 2025

First Online: 19 March 2025

Declarations

:

: All data used in this study were publicly available and anonymized. Thus, no ethical approval or informed consent was required.

: Not applicable.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below